

27 May 2026

Treatment of Secondary Cancers

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st January 2026 to the end of March 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	57
1.2 Apalutamide (Erleada)	21
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
1.4 Darolutamide (Nubeqa)	47
1.5 Enzalutamide (Xtandi)	152
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	85
1.8 Relugolix (Orgovyx, Ryego)	0
1.9 Olaparib (Lynparza)	26

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st January 2026 to the end of March 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	8
2.2 Olaparib (Lynparza) for prostate cancer	<5
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	0

27 May 2026

3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st January 2026 to the end of March 2026, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	12
3.2 Apalutamide (Erleada)	<5
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
3.4 Darolutamide (Nubeqa)	29
3.5 Enzalutamide (Xtandi)	16

4. How many patients were treated with the following combinations in the 3 months between 1st January 2026 to the end of March 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel	<5	<5
4.2 Darolutamide (Nubeqa) monotherapy	45	28
4.3 Olaparib (Lynparza) + Abiraterone	0	0

5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st January 2026 to the end of March 2026, or latest 3-months for which data are available?

**Not available in timeframe.

Name of medicine	Number patients treated
5.1 Abiraterone	
5.2 Enzalutamide	

27 May 2026

6. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between 1st January 2026 and 31st March 2026, or latest 3-month period for which data is available?

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
DARO3	Darolutamide in combination with androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel (TA1109)	0

* Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.